Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KADCYLA vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment,Treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination,Off-label: Use in HER2-positive advanced gastric cancer (limited data)
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
DM1 is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
93% bound to plasma proteins (trastuzumab component).
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Approximately 2.58 L/m² (central Vd), indicating limited extravascular distribution.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
100% (intravenous administration only).
Intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
No dose adjustment for mild hepatic impairment (Child-Pugh A). Not recommended for moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment due to lack of data.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy in pediatric patients have not been established.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged ≥65 years, but no overall differences in safety or efficacy were observed.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY Hepatotoxicity: Severe hepatotoxicity has been observed, including liver failure and death. Monitor liver function tests prior to each dose and as clinically indicated. Cardiac Toxicity: Left ventricular ejection fraction (LVEF) should be assessed prior to initiation and at regular intervals during treatment. Discontinue for clinically significant decline. Embryo-Fetal Toxicity: Exposure during pregnancy can cause embryo-fetal harm. Advise patients of these risks and need for effective contraception.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Hepatotoxicity: Monitor liver function tests; dose reduction or discontinuation may be required for elevated liver enzymes or bilirubin.,Cardiac toxicity: Assess LVEF before and during treatment; discontinue if symptomatic heart failure or significant asymptomatic decline.,Pulmonary toxicity: Interstitial lung disease (ILD) including pneumonitis has been reported; monitor for signs/symptoms and discontinue if confirmed.,Extravasation: Administer as IV infusion; extravasation may cause tissue necrosis. Ensure proper IV access.,Thrombocytopenia: Monitor platelet counts; dose modifications required for grade 3 or 4 thrombocytopenia.,Neuropathy: Peripheral neuropathy may occur; monitor and manage accordingly.,Embryo-fetal toxicity: Advise of risk and use effective contraception during and 7 months after treatment.,Increased intracranial pressure: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) reported; monitor and discontinue if occurs.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Known hypersensitivity to ado-trastuzumab emtansine or any of its components,Pregnancy (can cause embryo-fetal harm)
None known.
No specific food interactions are known for Kadcyla. However, avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and potentially increase exposure. Maintain a healthy diet to manage nausea and support overall health.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administered during the second and third trimesters. The DM1 component (emtansine) is a microtubule inhibitor with potential embryofetal toxicity. Based on its mechanism and animal studies, there is risk for teratogenicity in the first trimester, including structural anomalies. Avoid use during pregnancy unless benefit outweighs risk; advise effective contraception.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
It is not known whether Kadcyla is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, including tumorigenicity and developmental toxicity, advise women not to breastfeed during treatment and for at least 7 months after the last dose. M/P ratio is unknown.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No dose adjustment recommendations specific to pregnancy; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use only if clearly needed. Consider therapeutic drug monitoring if available, but no established target levels. Close maternal-fetal monitoring recommended.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Monitor left ventricular ejection fraction (LVEF) before and during treatment due to risk of cardiotoxicity. Infusion reactions are common; premedicate with antihistamines and corticosteroids. Do not substitute trastuzumab emtansine for trastuzumab or ado-trastuzumab emtansine. Avoid concomitant use with strong CYP3A4 inhibitors or inducers. Monitor for hepatotoxicity and pulmonary toxicity. Dose reduction required for thrombocytopenia or elevated transaminases.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
This drug is given as an IV infusion every 3 weeks. It may cause infusion reactions during or shortly after administration; tell your doctor immediately if you experience chills, fever, difficulty breathing, or chest pain.,Kadcyla can cause heart problems; you will have regular heart function tests (echocardiograms) before and during treatment. Report any new shortness of breath, cough, or swelling of ankles/legs.,This medication can cause liver damage; blood tests will be done to monitor liver function. Notify your doctor if you develop yellowing of skin/eyes, dark urine, or abdominal pain.,Kadcyla may lower platelet counts, increasing bleeding risk. Avoid activities that may cause injury or bruising. Report unusual bleeding or bruising.,This drug can cause severe birth defects; use effective contraception during treatment and for at least 7 months after the last dose. Do not breastfeed while taking Kadcyla.,You may experience fatigue, nausea, muscle/joint pain, or headache. Report persistent or severe symptoms to your healthcare provider.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KADCYLA vs COLUMVI, answered by our medical review team.
KADCYLA is a Antineoplastic Agent that works by KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KADCYLA and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KADCYLA is: 3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KADCYLA and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KADCYLA is classified as Category C. Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administer. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.